Stockscreener 앱 받기
3.81
1.33%
0.05
시간 외 거래:
3.84
0.03
+0.79%
Agenus Inc 주식(AGEN)의 최신 뉴스
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
MiNK Therapeutics (NASDAQ: INKT) names new financial leadership team - Stock Titan
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN
Research Analysts Issue Forecasts for Agenus Q1 Earnings - MarketBeat
Agenus Reports 2025 Financial Results, Advances BOT+BAL to Phase 3 with Expanding Global Access - Oncodaily
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer - The AI Journal
Price Action: Will Agenus Inc benefit from rate cuts2026 Setups & Verified Trade Idea Suggestions - baoquankhu1.vn
Agenus stock price target reaffirmed at $8 by B.Riley on revenue growth - Investing.com
Agenus reinforces commitment to global access as new innovation advances - Traders Union
Agenus Inc. 2025 Annual Report: Immuno-Oncology Strategy, Lead Programs, and Recent Developments - Minichart
Agenus reports $4.2M in early access revenue for cancer therapy By Investing.com - Investing.com South Africa
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Agenus: Fourth Quarter Financial Results Overview - Bitget
Agenus: Q4 Earnings Snapshot - Caledonian Record
Agenus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Agenus Inc. (AGEN) Releases Q4 2025 Earnings: Revenue Up but Wider Net Loss, Cash Plunges - Quiver Quantitative
Agenus 2025 10-K: $114.2M Revenue, $(0.00) EPS - TradingView
Agenus (NASDAQ: AGEN) leans on cancer lead BOT/BAL amid cash risk - Stock Titan
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Agenus Reports 2025 Progress: BOT+BAL Immunotherapy Advances to Phase 3 with Global Early Access Programs - Oncodaily
Market Fear: Why is Agenus Inc stock going down2026 Dividend Review & Trade Opportunity Analysis Reports - baoquankhu1.vn
(AGEN.O) | Stock Price & Latest News - Reuters
Agenus (AGEN) secures Zydus funding as BOT+BAL enters global Phase 3 - Stock Titan
Agenus reports $4.2M in early access revenue for cancer therapy - Investing.com
Agenus posts 42 percent 2 year OS and $4.2 million initial revenue on BOT plus BAL programs - Traders Union
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized - Business Wire
Earnings Scheduled For March 16, 2026 - Benzinga
Volume Summary: Should I invest in Agenus Inc before earningsMarket Performance Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Agenus Q4 2025 earnings preview - MSN
Agenus Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Immuno-oncology initiatives expand to address unmet cancer needs, Agenus asserts - Traders Union
Agenus receives $20M payment from Zydus collaboration By Investing.com - Investing.com Canada
Agenus receives $20M payment from Zydus collaboration - Investing.com Nigeria
Agenus (AGEN) Secures $20M Milestone Payment from Zydus Partners - GuruFocus
Agenus Triggers First $20 Million Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - marketscreener.com
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - Business Wire
Agenus (AGEN) director Garo Armen takes 4,994 shares as stock salary - Stock Titan
Agenus warns most metastatic colorectal cancer cases are MSS, calling for innovation to tackle resistance - Traders Union
Benny Johnson is Now The Executive Medical Director at Agenus - Oncodaily
Aug Patterns: Should I invest in Agenus Inc before earningsBuy Signal & Smart Money Movement Tracker - baoquankhu1.vn
How Agenus Inc. stock compares to market leaders2025 Bull vs Bear & Long-Term Safe Return Strategies - Naître et grandir
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update - marketscreener.com
Agenus (AGEN) to Release Earnings on Tuesday - MarketBeat
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
AGEN Technical Analysis & Stock Price Forecast - Intellectia AI
Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC - Finviz
Stock-paid salary boosts Armen’s Agenus (AGEN) share holdings - Stock Titan
How resilient is Agenus Inc. stock in market downturnsJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - mfd.ru
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL - BioSpace
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type - GlobeNewswire Inc.
AGEN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Why Agenus Inc. stock could outperform in 2025Weekly Risk Report & Real-Time Volume Trigger Notifications - mfd.ru
Why is Agenus Inc. stock going downJuly 2025 Reactions & Smart Allocation Stock Tips - mfd.ru
Response to the Misleading Open Letter by “Diaspora Leaders”: Statement by Dr. Garo Armen, Founder of the Children of Armenia Fund (COAF) - MassisPost
The Old System Failed Patients. Change Must Go Further and Faster – Garo Armen - Oncodaily
1.20%
0.06%
자본화:
|
볼륨(24시간):